Literature DB >> 10720035

The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome.

R Marcus1, D Leary, D L Schneider, E Shane, M Favus, C A Quigley.   

Abstract

Although androgen status affects bone mass in women and men, an androgen requirement for skeletal normalcy has not been established. Women with androgen insensitivity syndrome (AIS) have 46,XY genotypes with androgen receptor abnormalities rendering them partially or completely refractory to androgen. Twenty-eight women with AIS (22 complete and 6 high grade partial), aged 11-65 yr, responded to questionnaires about health history, gonadal surgery, and exogenous estrogen use and underwent bone mineral density (BMD) assessment by dual energy x-ray absortiometry. BMD values at the lumbar spine and proximal femur were compared to age-specific female normative values and listed as z-scores. Average height for adults in this cohort, 174 cm (68.5 in.), was moderately increased compared with the average height of adult American women of 162.3 cm, with skewing toward higher values: 5 women exceeded 6 ft in height, and 30% of the 18 adult women with complete AIS exceeded 5 ft, 11 in. in height. The average lumbar spine and hip BMD z-scores of the 6 women with partial AIS did not differ from population norms. In contrast, the average lumbar spine BMD z-score of women with complete AIS was significantly reduced at -1.08 (P = 0.0003), whereas the average value for hip BMD did not differ from normal. When BMD was compared between women who reported good estrogen replacement therapy compliance and those who reported poor compliance, there was a significantly greater deficit at the spine for women with poor compliance (z = -2.15 +/- 0.15 vs. -0.75 +/- 0.28; P < .0001). Furthermore, hip BMD was also significantly reduced in the noncompliant group (z = -0.95 +/- .40). Comparison of BMD values to normative male standards gave z-score reductions (z = -1.81 +/- 0.36) greater than those observed with female standards. Because of the high prevalence of tall stature in this study sample, we calculated bone mineral apparent density, a variable that adjusts for differences in bone size. Even for the estrogen-compliant group, bone mineral apparent density z-scores were subnormal at both the spine (z = -1.3 +/- 0.43; P < 0.01) and the hip (z = -1.38 +/- 0.28; P = 0.017). Six women with complete AIS had sustained cortical bone fractures, of whom 3 reported multiple (>3) fractures. We conclude that even when compliance to exogenous estrogen use is excellent, women with complete AIS show moderate deficits in spine BMD, averaging close to 1 SD from normative means, and that with correction of BMD for bone size, skeletal deficits are magnified and include the proximal femur. The results suggest that severe osteopenia in some women with AIS probably reflects a component of inadequate estrogen replacement rather than androgen lack alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720035     DOI: 10.1210/jcem.85.3.6428

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  Osteoporosis in men.

Authors:  G M Prelevic
Journal:  J R Soc Med       Date:  2001-12       Impact factor: 5.344

2.  Gonadal steroid-dependent effects on bone turnover and bone mineral density in men.

Authors:  Joel S Finkelstein; Hang Lee; Benjamin Z Leder; Sherri-Ann M Burnett-Bowie; David W Goldstein; Christopher W Hahn; Sarah C Hirsch; Alex Linker; Nicholas Perros; Andrew B Servais; Alexander P Taylor; Matthew L Webb; Jonathan M Youngner; Elaine W Yu
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

Review 3.  Minireview: nuclear receptor regulation of osteoclast and bone remodeling.

Authors:  Zixue Jin; Xiaoxiao Li; Yihong Wan
Journal:  Mol Endocrinol       Date:  2014-12-30

4.  Rates of bone loss in young adult males.

Authors:  Bonny L Specker; Howard E Wey; Eric P Smith
Journal:  Int J Clin Rheumtol       Date:  2010-04-01

Review 5.  Testicular function and bone metabolism--beyond testosterone.

Authors:  Alberto Ferlin; Riccardo Selice; Umberto Carraro; Carlo Foresta
Journal:  Nat Rev Endocrinol       Date:  2013-07-16       Impact factor: 43.330

6.  The Effects of Androgens on Murine Cortical Bone Do Not Require AR or ERα Signaling in Osteoblasts and Osteoclasts.

Authors:  Serra Ucer; Srividhya Iyer; Shoshana M Bartell; Marta Martin-Millan; Li Han; Ha-Neui Kim; Robert S Weinstein; Robert L Jilka; Charles A O'Brien; Maria Almeida; Stavros C Manolagas
Journal:  J Bone Miner Res       Date:  2015-07       Impact factor: 6.741

Review 7.  The role of estrogen and androgen receptors in bone health and disease.

Authors:  Stavros C Manolagas; Charles A O'Brien; Maria Almeida
Journal:  Nat Rev Endocrinol       Date:  2013-09-17       Impact factor: 43.330

8.  Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene.

Authors:  D L S Danilovic; P H S Correa; E M F Costa; K F S Melo; B B Mendonca; I J P Arnhold
Journal:  Osteoporos Int       Date:  2006-11-01       Impact factor: 4.507

Review 9.  Recent experimental and clinical findings in the skeleton associated with loss of estrogen hormone or estrogen receptor activity.

Authors:  Eric P Smith; Bonny Specker; Kenneth S Korach
Journal:  J Steroid Biochem Mol Biol       Date:  2009-11-10       Impact factor: 4.292

10.  Impact on bone of an estrogen receptor-alpha gene loss of function mutation.

Authors:  Eric P Smith; Bonny Specker; Bert E Bachrach; K S Kimbro; X J Li; Marian F Young; Neal S Fedarko; M J Abuzzahab; Graeme R Frank; Robert M Cohen; Dennis B Lubahn; Kenneth S Korach
Journal:  J Clin Endocrinol Metab       Date:  2008-05-27       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.